Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1475-1479

  Nagai, Yutaka ^a   Toita, Takafumi ^a   Wakayama, Akihiko ^a   Nakamoto, Tomoko ^a   Ooyama, Takuma ^a   Tokura, Akemi ^a   Inamine, Morihiko ^a   Kudaka, Wataru ^a   Murayama, Sadayuki ^a   Aoki, Yoichi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Cervical adenocarcinoma; Chemoradiotherapy; Cisplatin; Paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; CISPLATIN; CREATININE; PACLITAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA ANALYSIS; FEMALE; HUMAN; LEUKOCYTE COUNT; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84859960940     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Smith HO, Tiffany MF, Quails CR and Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - A 24-year populationbased study. Gynecol Oncol 78: 97-105, 2000. (Pubitemid 30650338)
2. Sasieni P and Adams J: Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 357: 1490-1493, 2001. (Pubitemid 32488859)
3. Eifel PJ, Burke TW, Morris M and Smith TL: Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59: 38-44, 1995.
4. Lai CH, Hsueh S, Hong JH, Chang TC, Tseng CJ, Chou HH, Huang KG and Lin JD: Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int J Gynecol Cancer 9: 28-36, 1999. (Pubitemid 29095787)
5. Chen RJ, Chang DY, Yen ML, Ue EF, Huang SC, Chow SN and Hsieh CY: Prognostic factors of primary adenocarcinoma of the uterine cervix. Gynecol Oncol 69: 157-164, 1998.
6. Natsume N, Aoki Y, Kase H, Kashima K, Sugaya S and Tanaka K: Ovarian metastasis in stage IB and II cervical adenocarcinoma. Gynecol Oncol 74: 255-258, 1999. (Pubitemid 29377222)
7. Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Hsueh S, Chen CK, Lee SP and Hong JH: Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 80: 429-436, 2011.
8. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340: 1137-1143, 1999. (Pubitemid 29177872)
9. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr. and Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18: 1606-1613, 2000. (Pubitemid 30220538)
10. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340: 1144-1153, 1999. (Pubitemid 29177873)
11. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL and Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17: 1339-1348, 1999. (Pubitemid 29220838)
12. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL and Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 540: 1154-1161, 1999. (Pubitemid 29177874)
13. Hirakawa M, Nagai Y, Inamine M, Kamiyama K, Ogawa K, Toita T, Murayama S and Aoki Y: Predictive factors of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol 108: 126-129, 2008. (Pubitemid 350299433)
14. Chen MD, Paley PJ, Potish RA and Twiggs LB: Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 67: 131-136, 1997. (Pubitemid 27500407)
15. Eifel PJ, Bruke TW, Morris M and Smith TL: Adenocarcinoma as an independent risk factor disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59: 38-44, 1995.
16. Grigsby PW, Perez CA, Kuske RR, Camel HM, Kao MS, Galakatos AE and Hederman MA: Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol 12: 289-296, 1998.
17. Niibe Y, Kenjo M, Onishi H, Ogawa Y, Kazumoto T, Ogino I, Tsujino K, Harima Y, Takahashi T, Anbai A, Tsuchida E, Toita T, Takemoto M, Yamashita H and Hayakawa K: High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IHb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007). Jpn J Clin Oncol 40: 795-799, 2010.
18. Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 17: 2676-2680, 1999. (Pubitemid 29415223)
19. Liebmann J, Cook JA, Fisher J Teague D and Mitchell JB: In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86: 441-446, 1994. (Pubitemid 24081876)
20. Rodrigues M, Seven BU, Perras J, Nguyen HN, Pham C, Steren AJ, Koechli OR and Averette HE: Paclitaxel: a radiation sensitizer of human cervical cancer cells. Gynecol Oncol 57: 165-169, 1995.
21. Pignata S, Frezza P, Tramontana S, Perrone F, Tambaro R, Casella G, Ferrari E, Iodice F, De Vivo R, Ricchi P, Tramontana F and Silvestro G: Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol 11: 455-459, 2000. (Pubitemid 30333550)
22. DiSilvestro PA, Walker JL, Morrison A, Rose PG, Homesley H, and Warshal D; Gynecologic Oncology Group: Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. Gynecol Oncol 103: 1038-1042, 2006. (Pubitemid 44821331)
23. Umayahara K, Takeshima N, Nose T, Fujiwara K, Sugiyama Y, Utsugi K, Yamashita T and Takizawa K: Phase I study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel chemotherapy for locally advanced cervical carcinoma in Japanese women. Int J Gynecol Cancer 19: 723-727, 2009.
24. Prasad E, Viswanathan PN, Rangad VF, Pavamani S and Ram TS: Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix. Clin Oncol (R Coll Radiol) 21: 488-493, 2009.